🔍 Investigations often miss systemic problems, leading to ineffective retraining.
📊 A deeper analysis can reduce incidents and improve safety, effectiveness, and product quality.
🤖 Emphasizing human factors may enhance the integration of AI and automation in drug manufacturing.
Introduction:
The article discusses the oversimplified attribution of manufacturing problems in the pharmaceutical industry to “human error,” emphasizing that this perspective often obscures the identification of underlying systemic issues. Ann Ryan, a researcher, argues for a more nuanced understanding of “human factors” that influence operational performance in drug manufacturing.
- The tendency to blame “human error” for manufacturing issues can misrepresent the complex interactions and failures within the pharmaceutical production processes.
- Research indicates that approximately 50% of quality incidents in pharmaceutical manufacturing are categorized as human error, but deeper investigations often reveal systemic problems instead.
- Human factors encompass conditions such as time constraints, inadequate tools, and facility design, which require a broader analytical approach beyond merely retraining personnel.
- Consideration of human factors is crucial for technology suppliers to design systems that are effective for diverse user capabilities and ergonomic contexts.
- Adopting a human factors perspective may enhance the implementation of AI and automation in drug manufacturing, improving safety and efficiency while addressing the complexity of human-machine interactions.
Conclusion:
The article concludes that recognizing and addressing human factors rather than solely attributing manufacturing deviations to human error is essential for improving biopharmaceutical processes. This shift in perspective can lead to better system designs and operational practices, ultimately enhancing product safety and efficacy.
